Literature DB >> 12438014

The genotoxic and cytotoxic effects of ribavirin in rat bone marrow.

K Narayana1, Urban J A D'Souza, K P Seetharama Rao.   

Abstract

The genotoxic and cytotoxic effects of the antiviral drug, ribavirin, was studied in rat bone marrow by employing the micronucleus assay. Ribavirin in doses of 10, 15, 20, 30, 50, 75, 100 and 200 mg/kg, and cyclophosphamide (CP) 40 mg/kg (only for sex-difference study) were injected intraperitoneally. Bone marrow was collected at 24 h and 48 h following the injection. To evaluate the recovery, the bone marrow was also sampled at 72 h from 20, 100 and 200 mg/kg treated rats. The micronucleus assay was conducted according to the standard procedure. Ribavirin elevated the incidence of micronuclei (except 10 mg/kg) in erythrocytes (P<0.01). The micronucleated polychromatic erythrocytes showed the initial steep increase at 15 and 20 mg/kg dose level, then with the gradual increase, possibly due to the limited metabolism and action of higher doses. The incidence of micronucleated normochromatic erythrocytes was not dose dependent. The effect was more at 48 h than 24 h due to prolonged toxicity of the drug or its metabolites, and by 72 h, recovery was observed even though the genotoxicity was significant. The PCE% decreased as the dose was increased up to 75 mg/kg, then without much difference between two higher doses. Only 100 mg/kg ribavirin and CP showed more toxicity on male rats. Cytotoxicity was seen due to hindered erythropoiesis or cell destruction. Our findings suggest that ribavirin is genotoxic and cytotoxic agent for rat bone marrow.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12438014     DOI: 10.1016/s1383-5718(02)00239-5

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  7 in total

Review 1.  Vitamin D and chronic hepatitis C: effects on success rate and prevention of side effects associated with pegylated interferon-α and ribavirin.

Authors:  Bassem Refaat; Adel Galal El-Shemi; Ahmed Ashshi; Esam Azhar
Journal:  Int J Clin Exp Med       Date:  2015-07-15

2.  Ribavirin induced anaemia: the effect of vitamin D supplementation on erythropoietin and erythrocyte indices in normal Wistar rat.

Authors:  Bassem Refaat; Tariq Helal Ashour; Adel Galal El-Shemi
Journal:  Int J Clin Exp Med       Date:  2014-09-15

3.  Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic.

Authors:  F Volpin; J Casaos; J Sesen; A Mangraviti; J Choi; N Gorelick; J Frikeche; T Lott; R Felder; S J Scotland; T S K Eisinger-Mathason; H Brem; B Tyler; N Skuli
Journal:  Oncogene       Date:  2016-12-12       Impact factor: 9.867

4.  Synthesis of 1-beta-D-ribofuranosyl-3-ethynyl-[1,2,4]triazole and its in vitro and in vivo efficacy against Hantavirus.

Authors:  Dong-Hoon Chung; Sidath C Kumarapperuma; Yanjie Sun; Qianjun Li; Yong-Kyu Chu; Jeffrey B Arterburn; William B Parker; Jeffrey Smith; Kristin Spik; Harish N Ramanathan; Connie S Schmaljohn; Colleen B Jonsson
Journal:  Antiviral Res       Date:  2008-03-17       Impact factor: 5.970

5.  A comparison of vitamin A and leucovorin for the prevention of methotrexate-induced micronuclei production in rat bone marrow.

Authors:  Sampath Madhyastha; Latha V Prabhu; V Saralaya; Rajalakshmi Rai
Journal:  Clinics (Sao Paulo)       Date:  2008-12       Impact factor: 2.365

6.  Inhibition of Chikungunya Virus Replication by 1-[(2-Methylbenzimidazol-1-yl) Methyl]-2-Oxo-Indolin-3-ylidene] Amino] Thiourea(MBZM-N-IBT).

Authors:  Priyadarsee Mishra; Abhishek Kumar; Prabhudutta Mamidi; Sameer Kumar; Itishree Basantray; Tanuja Saswat; Indrani Das; Tapas Kumar Nayak; Subhasis Chattopadhyay; Bharat Bhusan Subudhi; Soma Chattopadhyay
Journal:  Sci Rep       Date:  2016-02-04       Impact factor: 4.379

7.  Ribavirin as a potential therapeutic for atypical teratoid/rhabdoid tumors.

Authors:  Betty Tyler; Nicolas Skuli; Joshua Casaos; Sakibul Huq; Tarik Lott; Raphael Felder; John Choi; Noah Gorelick; Michael Peters; Yuanxuan Xia; Russell Maxwell; Tianna Zhao; Chenchen Ji; Thomas Simon; Julie Sesen; Sarah J Scotland; Richard E Kast; Jeffrey Rubens; Eric Raabe; Charles G Eberhart; Eric M Jackson; Henry Brem
Journal:  Oncotarget       Date:  2018-01-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.